Building a regulatory intelligence program from scratch starts with establishing a systematic process for monitoring, analyzing, and acting on regulatory developments that affect your products and markets. The foundation is choosing the right data sources, assigning clear ownership, and creating workflows that translate raw regulatory information into decisions. This article walks through each component, from what to include to how to measure whether the program is delivering value.
What does a regulatory intelligence program actually include?
A regulatory intelligence program is a structured system for continuously tracking, interpreting, and applying regulatory information relevant to your products, markets, and development pipeline. It covers guidelines, legislation, agency communications, scientific opinions, and competitive submissions, and it connects that information to internal decision-making processes.
At its core, the program has three layers. The first is monitoring, which means actively scanning regulatory sources on a defined schedule. The second is analysis, which means filtering what you find for relevance and assessing its impact on your specific products or strategies. The third is dissemination, which means getting the right information to the right people at the right time so it influences decisions before it becomes a compliance problem.
A well-designed program also includes a document management component, where regulatory updates are logged, versioned, and linked to the products or submissions they affect. Without this layer, intelligence gathering becomes a passive activity that rarely changes outcomes.
What regulatory data sources should you monitor?
The most important regulatory data sources to monitor are official agency websites, official journals, guidance document repositories, and structured alert services from bodies like the EMA, FDA, MHRA, and national competent authorities in your target markets. These primary sources should form the backbone of any regulatory intelligence program.
Beyond the primary sources, a complete monitoring setup typically includes:
- EMA and FDA guidance and concept papers for early signals of upcoming regulatory change
- Official Journal of the European Union for enacted legislation affecting medicinal products and medical devices
- ICH guidelines and consultation documents for harmonized technical requirements
- Notified body and competent authority communications for device-specific developments
- Scientific committee opinions from bodies such as CHMP, SCENIHR, and MDCG
- Competitor product approvals and label changes for market intelligence
- Industry association publications from organizations like RAPS, EuropaBio, and MedTech Europe
The temptation when building a program is to monitor everything. A more effective approach is to define your product scope and target markets first, then map which agencies and document types are directly relevant. A company focused on biologics in the EU has a different monitoring list than one commercializing class II medical devices in multiple global markets.
How do you structure a regulatory intelligence team?
A regulatory intelligence team works best when it has a designated owner responsible for the overall program, subject matter contributors who cover specific product areas or geographies, and a clear escalation path to senior regulatory and business leadership. The structure does not need to be large, but ownership must be explicit.
In early-stage companies with lean regulatory teams, one person often performs both intelligence gathering and regulatory affairs functions. This is workable if that person has a defined schedule for monitoring activities and a simple system for logging and sharing what they find. The risk in this model is that intelligence work gets deprioritized when submission deadlines dominate the calendar.
As the organization grows, a more sustainable model separates the monitoring and analysis function from submission work. This allows the intelligence function to operate proactively rather than reactively. Some companies also build regional contributors into the team structure, particularly when they operate across the EU, US, and Asia-Pacific simultaneously, since regulatory developments in each region move on different timelines and require different expertise.
What tools and systems support regulatory intelligence tracking?
Regulatory intelligence tracking is supported by a combination of purpose-built regulatory information management platforms, structured alert services, and internal knowledge management tools. The right combination depends on the complexity of your product portfolio and the number of markets you monitor.
Common tool categories include:
- Regulatory information management systems such as Veeva Vault RIM or ARIS Global, which centralize tracking and link updates to submissions and products
- Alert and monitoring services from providers that aggregate agency publications and flag changes by topic or product category
- Document management systems that store and version regulatory source documents alongside internal analysis notes
- Collaboration platforms for distributing intelligence summaries and capturing decisions made in response
- Spreadsheet-based trackers as a low-cost starting point for smaller teams monitoring a limited number of sources
For early-stage companies, the priority is establishing a consistent process rather than investing in expensive software immediately. A well-maintained shared document with defined update cycles often outperforms an underused enterprise platform. The tool should match the team’s capacity to actually use it.
How do you turn regulatory intelligence into actionable decisions?
Regulatory intelligence becomes actionable when it is connected to a formal impact assessment process that evaluates each relevant update against your current products, submissions, and development timelines, and assigns a responsible owner to respond. Without this step, intelligence gathering produces reports that inform without changing behavior.
A practical impact assessment process works as follows. When a relevant regulatory update is identified, the team assesses three things: whether it affects a current product or submission, whether it requires a change to an ongoing development program, and what the timeline for compliance or adaptation is. Each assessment produces a clear output, such as a submission amendment, a gap analysis, a strategy review, or no action required.
The intelligence then needs to reach the people who can act on it. This means regulatory intelligence outputs should be integrated into product development reviews, portfolio planning meetings, and regulatory strategy sessions rather than circulated as standalone reports. When intelligence informs a decision that is already being made, it has genuine influence. When it arrives as a separate briefing document, it is more likely to be filed and forgotten.
How do you know if your regulatory intelligence program is working?
A regulatory intelligence program is working when it consistently enables proactive responses to regulatory change rather than reactive ones, and when the team can demonstrate that intelligence inputs influenced specific decisions before those decisions became compliance issues. The clearest indicator is whether the program surfaces relevant changes before they create submission delays or product holds.
Useful indicators to track include:
- The number of regulatory updates identified and assessed per quarter, compared against what was actually published
- The lead time between a regulatory development being published and the team completing an impact assessment
- The proportion of assessments that resulted in a defined action versus no action required
- Whether any regulatory changes caused reactive scrambling that a better-functioning program would have caught earlier
- Feedback from regulatory strategy and product development teams on whether intelligence inputs are reaching them in a timely and useful format
Qualitative signals matter as much as quantitative ones. If product teams are proactively asking the regulatory intelligence function for updates before making decisions, the program has become embedded in the organization’s workflow. If intelligence is only consulted after a problem emerges, the program is functioning as a reference library rather than a strategic asset.
How Starodub supports your regulatory intelligence needs
Building a regulatory intelligence program requires both the right processes and the right expertise to interpret what regulatory developments actually mean for your specific products and markets. We work with biopharmaceutical and medical device companies at every stage to establish and strengthen regulatory intelligence capabilities that support real business decisions.
Our support in this area includes:
- Mapping the regulatory landscape for your product portfolio and target markets, including EU, US, and international requirements
- Identifying and prioritizing the data sources and agency communications most relevant to your product types and development stage
- Conducting impact assessments when significant regulatory changes occur, translating updates into clear implications for your submissions and strategy
- Providing ongoing regulatory monitoring as part of a broader regulatory affairs partnership, so intelligence work does not compete with your submission timelines
- Supporting classification and pathway decisions for complex products such as combination products, ATMPs, and software-based medical devices, where regulatory intelligence directly shapes strategy
With over 400 completed projects and more than 300 clients supported, we bring the depth of experience needed to distinguish signal from noise in a rapidly evolving regulatory environment. If you are building a regulatory intelligence program or want to strengthen an existing one, get in touch with our team to discuss how we can help.
Related Articles
- How long does it take to become GMP compliant?
- Technical Documentation for Medical Devices: What to Include Under MDR
- Drug-Device Combination Products: Regulatory Framework Explained
- How do breakthrough device designations accelerate regulatory approval?
- What are the emerging global medical device regulatory trends for 2026?
This content was generated with the help of AI and it may contain mistakes
